



Clinical trial results:

A Phase II, Two Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined with Idelalisib or Venetoclax in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton's Tyrosine Kinase (BTK) Inhibitor

Summary

EudraCT number	2015-002915-14
Trial protocol	AT GB DE FR IT
Global end of trial date	01 December 2021

Results information

Result version number	v1 (current)
This version publication date	04 August 2022
First version publication date	04 August 2022

Trial information

Trial identification

Sponsor protocol code	MOR208C205
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02639910
WHO universal trial number (UTN)	-
Other trial identifiers	US IND Number: 114,856

Notes:

Sponsors

Sponsor organisation name	MorphoSys AG
Sponsor organisation address	Simmelweisstr, 7, D-82152 Planegg, Germany,
Public contact	Medical Information, MorphoSys AG , +49 1 844 667-199, medinfo@morphosys.com
Scientific contact	Medical Information, MorphoSys AG , +49 1 844 667-199, medinfo@morphosys.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 January 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 December 2021
Global end of trial reached?	Yes
Global end of trial date	01 December 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the safety and preliminary efficacy of MOR00208 combined with Idelalisib or Venetoclax in patients with relapsed or refractory CLL/SLL previously treated with Bruton's Tyrosine Kinase (BTK) inhibitor.

Protection of trial subjects:

Independent Ethics Committee:

Prior to site initiation, the sponsor obtained written approval and favorable opinion from the appropriate regulatory bodies/local health authorities (in accordance with local regulations) and the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) to conduct the study in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and applicable country specific regulatory requirements. Approval was required for the study protocol, Investigator's Brochure, protocol amendments, Informed Consent Forms (ICFs), and Patient Information Sheets. No substantial changes to the final approved protocol were initiated without the prior written approval and favorable opinion of the IRB/IEC and approval by the regulatory bodies/local health authorities of a written amendment, except when necessary to eliminate immediate hazards to the patients or when the change involves only logistics or administration.

Ethical Conduct of the Study:

This clinical study was designed, conducted, and reported in accordance with ICH GCP guidelines, applicable local regulations, and with the ethical principles laid down in the Declaration of Helsinki, including, but not limited to:

- 1) IRB/IEC review and favorable opinion/approval of the study protocol.
- 2) Patient informed consent.
- 3) Investigator reporting requirements.

The sponsor provided full details of the above procedures, verbally, in writing, or both.

Patient information and Consent:

Prior to any protocol related activities, the investigator obtained freely given written consent from each patient after an appropriate explanation of the aims, methods, anticipated benefits, potential hazards and any other aspect of the study that was relevant to the patient's decision to participate. The ICF was signed, with name and date noted by the patient, before the patient was exposed to any study related procedure including screening tests for eligibility.

Background therapy:

Patients were allowed to continue the medications that they were taking at baseline. Medications to treat concomitant diseases, e.g., diabetes, hypertension, bronchial asthma, and COPD were allowed. Patients also received therapy to mitigate side effects of the study medication as clinically indicated, as well as best supportive care as per institutional guidelines. This could have included, e.g., antiemetics, antidiarrheals, anticholinergics, antispasmodics, antipyretics, antihistamines, analgesics, antibiotics, and other medications intended to treat symptoms. The investigator had to instruct the patient not to take any additional medications (including over the counter products) during the study without prior consultation. Investigators documented all medications (e.g., prescription drugs, over the counter drugs, herbal or homeopathic remedies, nutritional supplements) taken within 30 days prior to signature of the ICF.

Evidence for comparator: -

Actual start date of recruitment	09 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 5
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	Austria: 6
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	United States: 6
Worldwide total number of subjects	24
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	11
From 65 to 84 years	13
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Age ≥ 18 years.

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that met International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic criteria and histologically confirmed.

Patients must have relapsed or refractory disease

Most recent anticancer therapy with BTK inhibitor (e.g., ibrutinib)

Pre-assignment

Screening details:

CT/MRI scan had to be performed within 14 days before C1D1. CT scans performed prior to screening as part of the regular clinical workup of the patient was allowed up to 6 weeks before C1D1. tumor lysis syndrome risk assessment as per IWCLL guideline could have been obtained from CLL history or otherwise obtained from baseline investigation.

Period 1

Period 1 title	Treatment Period 1
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort A Safety and Efficacy = MOR00208 + Idelalisib

Arm description:

MOR00208 Dose:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.

Idelalisib dose:

Patients self-administered the starting dose of 150 mg twice daily orally, continuously during the study

Arm type	Experimental
Investigational medicinal product name	Tafasitamab
Investigational medicinal product code	MOR00208
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 each cycle from C7D1. MOR00208 is a lyophilized powder for reconstitution for intravenous infusion. For administration, MOR00208 was diluted into a commercially available 250 mL infusion container with 0.9% (w/v) sodium chloride for injection. It was used in combination with Idelalisib (100, 150mg tablets).

Arm title	Cohort B Safety = MOR00208 + Venetoclax
------------------	---

Arm description:

MOR00208 Dose:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.

Venetoclax Dose:

To mitigate the risk for tumor lysis syndrome (TLS), treatment of patients with oral venetoclax was initiated at a dose of 20 mg daily from C1D8 for 7 days, followed by a weekly ramp-up schedule (50 mg, 100 mg, 200 mg daily dose) to the recommended daily dose of 400 mg, starting from C2D8. Patients self-administered venetoclax throughout the study except for during hospitalization.

NOTE: No venetoclax was administered to 2 patients as they had IRR to MOR00208 during the first infusion at C1D1 and study drug treatment.

Arm type	Experimental
Investigational medicinal product name	Tafasitamab
Investigational medicinal product code	MOR00208
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 each cycle from C7D1. MOR00208 is a lyophilized powder for reconstitution for intravenous infusion. For administration, MOR00208 was diluted into a commercially available 250 mL infusion container with 0.9% (w/v) sodium chloride for injection. It was used in combination with Venetoclax (10, 50, 100mg tablets).

Number of subjects in period 1	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Safety = MOR00208 + Venetoclax
Started	11	13
Completed	11	13

Period 2

Period 2 title	Treatment Period 2
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort A Safety and Efficacy = MOR00208 + Idelalisib

Arm description:**MOR00208 Dose:**

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.

Idelalisib dose:

Patients self-administered the starting dose of 150 mg twice daily orally, continuously during the study
NOTE: Treatment with MOR00208 and idelalisib or venetoclax continued for up to 24 cycles or longer at the investigator's discretion or until documented disease progression, intolerable toxicity, withdrawal of

consent to continue study treatment, death, or early termination of the study. Completion has been defined for Period 2 as having completed EOT and 30-day-FU visit.

Arm type	Experimental
Investigational medicinal product name	Tafasitamab
Investigational medicinal product code	MOR00208
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 each cycle from C7D1. MOR00208 is a lyophilized powder for reconstitution for intravenous infusion. For administration, MOR00208 was diluted into a commercially available 250 mL infusion container with 0.9% (w/v) sodium chloride for injection. It was used in combination with Idelalisib (100, 150mg tablets).

Arm title	Cohort B Efficacy = MOR00208 + Venetoclax
------------------	---

Arm description:

MOR00208 Dose:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.

Venetoclax Dose:

To mitigate the risk for tumor lysis syndrome (TLS), treatment of patients with oral venetoclax was initiated at a dose of 20 mg daily from C1D8 for 7 days, followed by a weekly ramp-up schedule (50 mg, 100 mg, 200 mg daily dose) to the recommended daily dose of 400 mg, starting from C2D8. Patients self-administered venetoclax throughout the study except for during hospitalization.

Arm type	Experimental
Investigational medicinal product name	Tafasitamab
Investigational medicinal product code	MOR00208
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 each cycle from C7D1. MOR00208 is a lyophilized powder for reconstitution for intravenous infusion. For administration, MOR00208 was diluted into a commercially available 250 mL infusion container with 0.9% (w/v) sodium chloride for injection. It was used in combination with Venetoclax (10, 50, 100mg tablets).

Number of subjects in period 2	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Efficacy = MOR00208 + Venetoclax
Started	11	13
Completed	6	8
Not completed	5	5
Adverse event, serious fatal	2	1
Consent withdrawn by subject	-	2
Adverse event, non-fatal	-	1
Progressive Disease	3	-
Not specified	-	1

Baseline characteristics

Reporting groups

Reporting group title	Treatment Period 1
Reporting group description: -	

Reporting group values	Treatment Period 1	Total	
Number of subjects	24	24	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	11	11	
From 65-84 years	13	13	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	64.9		
standard deviation	± 8.5	-	
Gender categorical			
Units: Subjects			
Female	8	8	
Male	16	16	

Subject analysis sets

Subject analysis set title	Safety analysis set
Subject analysis set type	Safety analysis
Subject analysis set description: The SAF included all patients who received at least one dose of any study drug and had at least one post-baseline safety evaluation	
Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set (FAS) consisted of all patients who received at least one dose of MOR00208 and/or one dose of idelalisib in Cohort A and/or one dose of venetoclax in Cohort B.	
Subject analysis set title	PK Analysis Set
Subject analysis set type	Sub-group analysis
Subject analysis set description: The PKAS included all patients who received at least one dose of MOR00208 and had at least one quantifiable serum MOR00208 concentration. In Cohort B, 1 patient had no quantifiable serum MOR00208 concentration and was excluded from the PKAS.	
Subject analysis set title	Immunogenicity Analysis Set
Subject analysis set type	Sub-group analysis

Subject analysis set description:

The IAS included all patients who had at least one anti-MOR00208 antibody assessment. The reason for exclusion of 1 patient from IAS population was no anti-MOR00208 antibody assessment.

Reporting group values	Safety analysis set	Full analysis set	PK Analysis Set
Number of subjects	24	24	23
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	11	11	10
From 65-84 years	13	13	13
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	64.9	64.9	65.3
standard deviation	± 8.5	± 8.5	± 8.4
Gender categorical Units: Subjects			
Female	8	8	8
Male	16	16	15

Reporting group values	Immunogenicity Analysis Set		
Number of subjects	23		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	11		
From 65-84 years	12		
85 years and over	0		
Age continuous Units: years			
arithmetic mean	64.3		
standard deviation	± 8.1		
Gender categorical Units: Subjects			
Female	8		
Male	15		

End points

End points reporting groups

Reporting group title	Cohort A Safety and Efficacy = MOR00208 + Idelalisib
Reporting group description:	
MOR00208 Dose: For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.	
Idelalisib dose: Patients self-administered the starting dose of 150 mg twice daily orally, continuously during the study	
Reporting group title	Cohort B Safety = MOR00208 + Venetoclax
Reporting group description:	
MOR00208 Dose: For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.	
Venetoclax Dose: To mitigate the risk for tumor lysis syndrome (TLS), treatment of patients with oral venetoclax was initiated at a dose of 20 mg daily from C1D8 for 7 days, followed by a weekly ramp-up schedule (50 mg, 100 mg, 200 mg daily dose) to the recommended daily dose of 400 mg, starting from C2D8. Patients self-administered venetoclax throughout the study except for during hospitalization. NOTE: No venetoclax was administered to 2 patients as they had IRR to MOR00208 during the first infusion at C1D1 and study drug treatment.	
Reporting group title	Cohort A Safety and Efficacy = MOR00208 + Idelalisib
Reporting group description:	
MOR00208 Dose: For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.	
Idelalisib dose: Patients self-administered the starting dose of 150 mg twice daily orally, continuously during the study NOTE: Treatment with MOR00208 and idelalisib or venetoclax continued for up to 24 cycles or longer at the investigator's discretion or until documented disease progression, intolerable toxicity, withdrawal of consent to continue study treatment, death, or early termination of the study. Completion has been defined for Period 2 as having completed EOT and 30-day-FU visit.	
Reporting group title	Cohort B Efficacy = MOR00208 + Venetoclax
Reporting group description:	
MOR00208 Dose: For the first 3 months of the study, each 28-day cycle consisted of a MOR00208 intravenous infusion of the dose of 12 mg/kg on Day 1, Day 8, Day 15, and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter, MOR00208 was administered on a bi-weekly basis (every 14 days) with infusions on Days 1 and 15 of each cycle from Cycle 4 to 6, and on a monthly basis on Day 1 of each cycle from C7D1.	
Venetoclax Dose: To mitigate the risk for tumor lysis syndrome (TLS), treatment of patients with oral venetoclax was initiated at a dose of 20 mg daily from C1D8 for 7 days, followed by a weekly ramp-up schedule (50 mg, 100 mg, 200 mg daily dose) to the recommended daily dose of 400 mg, starting from C2D8. Patients self-administered venetoclax throughout the study except for during hospitalization.	
Subject analysis set title	Safety analysis set
Subject analysis set type	Safety analysis
Subject analysis set description:	
The SAF included all patients who received at least one dose of any study drug and had at least one post-baseline safety evaluation	

Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description:	
The full analysis set (FAS) consisted of all patients who received at least one dose of MOR00208 and/or one dose of idelalisib in Cohort A and/or one dose of venetoclax in Cohort B.	
Subject analysis set title	PK Analysis Set
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
The PKAS included all patients who received at least one dose of MOR00208 and had at least one quantifiable serum MOR00208 concentration. In Cohort B, 1 patient had no quantifiable serum MOR00208 concentration and was excluded from the PKAS.	
Subject analysis set title	Immunogenicity Analysis Set
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
The IAS included all patients who had at least one anti-MOR00208 antibody assessment. The reason for exclusion of 1 patient from IAS population was no anti-MOR00208 antibody assessment.	

Primary: Incidence of adverse events after combination and single therapy in safety analysis set (SAF)

End point title	Incidence of adverse events after combination and single therapy in safety analysis set (SAF) ^[1]
End point description:	
The Safety analysis set (SAF) included all patients who received at least one dose of MOR00208 and/or one dose of idelalisib or venetoclax. Analyses using the SAF were based on the study drug actually received. The SAF was used for the primary endpoint analysis, i.e., incidence.	
End point type	Primary
End point timeframe:	
Cycle 1 to EOT (End of treatment).	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned.

End point values	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Safety = MOR00208 + Venetoclax	Safety analysis set	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	11	13	24	
Units: Number of subjects	11	13	24	

Statistical analyses

No statistical analyses for this end point

Primary: Severity of adverse events after single and combination therapy in safety analysis set (SAF)

End point title	Severity of adverse events after single and combination therapy in safety analysis set (SAF) ^[2]
End point description:	
TEAEs were defined as AEs which began or worsened in severity after the first administration of study drug (MOR00208, Idelalisib or Venetoclax) until 30 days after the last study treatment. AEs that	

occurred or worsened later than 30 days after the last treatment of any study drug were defined as treatment-emergent if these were suspected to be related to the pertaining study drug. MOR00208-related TEAEs with toxicity Grade 3 or 4 was included based on the number of patients in the safety analysis set.

End point type	Primary
End point timeframe:	
Cycle 1 to EOT (End of treatment).	
Notes:	
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: No formal statistical hypothesis testing was planned.	

End point values	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Safety = MOR00208 + Venetoclax	Safety analysis set	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	11	13	24	
Units: Number of subjects	9	9	18	

Statistical analyses

No statistical analyses for this end point

Secondary: Best objective response rate (ORR) after combination therapy local evaluation in full analysis set (FAS)

End point title	Best objective response rate (ORR) after combination therapy local evaluation in full analysis set (FAS)
End point description:	
Objective response included complete response (CR), Partial response (PR) and Partial response with lymphocytosis (PRL) categories for MOR00208 + Idelalisib and CR and PR categories for MOR00208 + Venetoclax.	
End point type	Secondary
End point timeframe:	
Cycle 1 to EOT (End of treatment).	

End point values	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Efficacy = MOR00208 + Venetoclax	Full analysis set	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	11	13	24	
Units: Number of subjects	10	10	20	

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment emergent Anti-MOR00208 antibody formation after combination therapy in immunogenicity analysis set (IAS)

End point title	Treatment emergent Anti-MOR00208 antibody formation after combination therapy in immunogenicity analysis set (IAS)
-----------------	--

End point description:

Treatment emergent Anti-MOR00208 antibody formation after combination therapy in immunogenicity analysis set (IAS).

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 to EOT (End of treatment).

End point values	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Efficacy = MOR00208 + Venetoclax	Immunogenicit y Analysis Set	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	10	13	23	
Units: Number of subjects	3	0	3	

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum plasma concentration (Cmax) of MOR00208 after combination therapy in pharmacokinetics analysis set (PKAS)

End point title	Maximum plasma concentration (Cmax) of MOR00208 after combination therapy in pharmacokinetics analysis set (PKAS)
-----------------	---

End point description:

Maximum plasma concentration (Cmax) of MOR00208 after combination therapy in pharmacokinetics analysis set (PKAS).

End point type	Secondary
----------------	-----------

End point timeframe:

At Cycle 3 Day 15.

End point values	Cohort A Safety and Efficacy = MOR00208 + Idelalisib	Cohort B Efficacy = MOR00208 + Venetoclax	PK Analysis Set	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	6	7	13	
Units: nanogram(s)/millilitre				
arithmetic mean (standard deviation)	482148.3 (±	532045.7 (±	509016.2 (±	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first administration of any study drug (MOR00208, Idelalisib or Venetoclax) to the patient until the 30-day safety follow-up visit.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.0

Reporting groups

Reporting group title	Cohort A = MOR00208 + Idelalisib
-----------------------	----------------------------------

Reporting group description: -

Reporting group title	Cohort B = MOR00208 + Venetoclax
-----------------------	----------------------------------

Reporting group description: -

Reporting group title	Cohort B = MOR00208 Only
-----------------------	--------------------------

Reporting group description:

No venetoclax was administered to these 2 patients as they had IRR to MOR00208 during the first infusion at C1D1 and study drug treatment was permanently discontinued.

Serious adverse events	Cohort A = MOR00208 + Idelalisib	Cohort B = MOR00208 + Venetoclax	Cohort B = MOR00208 Only
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 11 (36.36%)	3 / 11 (27.27%)	2 / 2 (100.00%)
number of deaths (all causes)	2	1	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 11 (0.00%)	2 / 2 (100.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			

subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Non-serious adverse events	Cohort A = MOR00208 + Idelalisib	Cohort B = MOR00208 + Venetoclax	Cohort B = MOR00208 Only
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	11 / 11 (100.00%)	1 / 2 (50.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
Lung neoplasm			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Meningioma			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 11 (18.18%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	2	1	0
Aortic dilatation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Circulatory collapse			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Flushing			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	2	0

Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Orthostatic hypotension			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Peripheral venous disease			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Poor peripheral circulation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Vascular calcification			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 11 (18.18%)	5 / 11 (45.45%)	0 / 2 (0.00%)
occurrences (all)	3	6	0
Pyrexia			
subjects affected / exposed	5 / 11 (45.45%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	13	2	0
Asthenia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Chills			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
General physical health deterioration			
subjects affected / exposed	2 / 11 (18.18%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Oedema peripheral			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	2	1	0
Catheter site haematoma			

subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Catheter site irritation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Chest discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Drug intolerance			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Face oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Feeling hot			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gait disturbance			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Illness			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Immunodeficiency			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Contrast media allergy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Drug hypersensitivity			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Graft versus host disease in liver subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 2	0 / 2 (0.00%) 0
Reproductive system and breast disorders			
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	6 / 11 (54.55%) 9	5 / 11 (45.45%) 6	0 / 2 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	6 / 11 (54.55%) 7	3 / 11 (27.27%) 3	0 / 2 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 4	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Atelectasis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 11 (0.00%) 0	1 / 2 (50.00%) 1
Dyspnoea exertional subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Haemothorax subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Increased bronchial secretion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Productive cough			

subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pulmonary oedema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Sinus disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Small airways disease			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Tachypnoea			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pneumothorax			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 11 (9.09%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	1	2	0

Agitation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Depressed mood			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Sleep disorder			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Investigations			
Weight decreased			
subjects affected / exposed	3 / 11 (27.27%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	3	4	0
Alanine aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 11 (9.09%)	1 / 2 (50.00%)
occurrences (all)	2	1	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 11 (0.00%)	4 / 11 (36.36%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
C-reactive protein increased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	3	1	0
Troponin T increased			
subjects affected / exposed	0 / 11 (0.00%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Amylase increased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	3	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	1 / 2 (50.00%)
occurrences (all)	0	1	1
Blood immunoglobulin G decreased			

subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Coombs test positive			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	4	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 11 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Body temperature increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Digestive enzyme increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram T wave abnormal			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
International normalised ratio increased			

subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	3	0	0
Lipase increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Prothrombin time prolonged			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Sapovirus test positive			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Troponin increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Weight increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	5 / 11 (45.45%)	5 / 11 (45.45%)	0 / 2 (0.00%)
occurrences (all)	5	7	0
Arthropod bite			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Fall			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Medication error			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Overdose			

subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Post vaccination syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Skin injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Tendon rupture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	1 / 2 (50.00%)
occurrences (all)	0	1	1
Arrhythmia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Atrial fibrillation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Atrioventricular block			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Atrioventricular block second degree			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Cardiovascular insufficiency			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Coronary artery disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Mitral valve incompetence subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Myocardial ischaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Tachyarrhythmia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Tricuspid valve incompetence subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 3	3 / 11 (27.27%) 6	0 / 2 (0.00%) 0
Burning sensation subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Complex regional pain syndrome subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Lethargy			

subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	5 / 11 (45.45%)	5 / 11 (45.45%)	1 / 2 (50.00%)
occurrences (all)	16	26	1
Anaemia			
subjects affected / exposed	6 / 11 (54.55%)	4 / 11 (36.36%)	0 / 2 (0.00%)
occurrences (all)	7	6	0
Leukopenia			
subjects affected / exposed	1 / 11 (9.09%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	1	4	0
Thrombocytopenia			
subjects affected / exposed	3 / 11 (27.27%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	3	1	0
Lymphopenia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Anaemia of malignant disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Leukocytosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 11 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Splenic infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Deafness			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Deafness unilateral			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Ear discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dacryostenosis acquired			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Erythema of eyelid			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Holmes-Adie pupil			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Pupils unequal			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Visual impairment			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Vitreous detachment			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	5 / 11 (45.45%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	7	5	0
Nausea			
subjects affected / exposed	2 / 11 (18.18%)	5 / 11 (45.45%)	0 / 2 (0.00%)
occurrences (all)	2	8	0
Dyspepsia			
subjects affected / exposed	0 / 11 (0.00%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	1 / 2 (50.00%)
occurrences (all)	0	2	1
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Anal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Diverticulum			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Dry mouth			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Dysphagia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Erosive duodenitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Erosive oesophagitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Gastritis erosive			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Glossitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Haematochezia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Inguinal hernia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Noninfective sialoadenitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Umbilical hernia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hepatobiliary disorders			
Cholelithiasis subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 3	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hydrocholecystis subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	2 / 11 (18.18%) 2	0 / 2 (0.00%) 0
Hepatic cyst subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hepatic lesion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hepatotoxicity subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Skin and subcutaneous tissue disorders			
Skin lesion subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	3 / 11 (27.27%) 5	0 / 2 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hyperhidrosis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 11 (9.09%) 2	0 / 2 (0.00%) 0
Skin haemorrhage			

subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Alopecia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	5	0
Onychoclasia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Skin mass			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hydronephrosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pyelocaliectasis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Renal failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Renal impairment			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Urine flow decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Myalgia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Pain in extremity			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Back pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Exostosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Intervertebral disc disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Joint swelling			

subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Muscle atrophy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Myopathy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Osteosclerosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Spondylolisthesis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Respiratory tract infection			
subjects affected / exposed	2 / 11 (18.18%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	2	4	0
Urinary tract infection			
subjects affected / exposed	4 / 11 (36.36%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	7	1	0
Pneumonia			
subjects affected / exposed	1 / 11 (9.09%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
Sinusitis			
subjects affected / exposed	1 / 11 (9.09%)	3 / 11 (27.27%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 11 (18.18%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	2	3	0

Nasopharyngitis			
subjects affected / exposed	2 / 11 (18.18%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	3	2	0
Bronchitis			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Cytomegalovirus infection			
subjects affected / exposed	2 / 11 (18.18%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Infection			
subjects affected / exposed	1 / 11 (9.09%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	2	1	0
Viral infection			
subjects affected / exposed	0 / 11 (0.00%)	2 / 11 (18.18%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Aspergillus infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Bacterial sepsis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Chronic sinusitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Erysipelas			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Escherichia infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Fungal oesophagitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Gastrointestinal candidiasis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Gastrointestinal infection subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Helicobacter gastritis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Helicobacter infection subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Infectious pleural effusion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 2	0 / 2 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Liver abscess subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Norovirus infection subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0

Staphylococcal infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Urinary tract infection enterococcal subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	0 / 2 (0.00%) 0
Metabolism and nutrition disorders			
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	4 / 11 (36.36%) 5	1 / 2 (50.00%) 1
Hypocalcaemia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	3 / 11 (27.27%) 3	0 / 2 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	2 / 11 (18.18%) 2	1 / 2 (50.00%) 1
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	3 / 11 (27.27%) 3	1 / 2 (50.00%) 1
Iron deficiency subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	3 / 11 (27.27%) 3	0 / 2 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 11 (0.00%) 0	1 / 2 (50.00%) 1
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 11 (9.09%) 1	0 / 2 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	1 / 2 (50.00%) 1
Hypomagnesaemia			

subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	1 / 2 (50.00%)
occurrences (all)	1	0	1
Decreased appetite			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Folate deficiency			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 11 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Hypermagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 11 (9.09%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Hypoproteinaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported.

Notes: